📊 TLPH Key Takeaways
Is Talphera, Inc.. (TLPH) a Good Investment?
Talphera is a pre-revenue pharmaceutical company burning approximately $3.4M annually with only ~13 months of cash runway at current burn rates. While the balance sheet maintains moderate leverage (0.31x debt-to-equity) and strong liquidity ratios, the absence of revenue generation, deteriorating year-over-year EPS trends (-122.6%), and lack of capital expenditure create substantial execution risk requiring near-term clinical or commercial milestones.
Why Buy Talphera, Inc.. Stock? TLPH Key Strengths
- Strong liquidity position with current ratio of 5.30x and quick ratio of 5.01x
- Moderate debt-to-equity ratio of 0.31x provides financial flexibility
- Reasonable stockholders' equity base of $18.5M relative to asset size
TLPH Stock Risks: Talphera, Inc.. Investment Risks
- Zero revenue with no clear path to near-term commercialization
- Negative operating cash flow of -$3.4M annually creating urgent refinancing need
- Limited cash runway of approximately 13 months at current burn rate
- Deteriorating profitability with -122.6% year-over-year EPS decline
- Absence of capital expenditure suggests limited product development investment for pharma sector
Key Metrics to Watch
- Cash balance and runway duration relative to quarterly burn rates
- Clinical trial progression and regulatory milestones
- Revenue recognition from any commercial or partnership activities
Talphera, Inc.. (TLPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.30x current ratio provides a solid financial cushion.
TLPH Profit Margin, ROE & Profitability Analysis
TLPH vs Healthcare Sector: How Talphera, Inc.. Compares
How Talphera, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Talphera, Inc.. Stock Overvalued? TLPH Valuation Analysis 2026
Based on fundamental analysis, Talphera, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Talphera, Inc.. Balance Sheet: TLPH Debt, Cash & Liquidity
TLPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Talphera, Inc..'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $5.72 reflects profitable operations.
TLPH Revenue Growth, EPS Growth & YoY Performance
TLPH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$2.6M | N/A |
| Q3 2025 | N/A | -$2.6M | N/A |
| Q2 2025 | N/A | -$2.6M | N/A |
| Q1 2025 | N/A | -$2.6M | $-0.10 |
| Q3 2024 | N/A | -$1.4M | N/A |
| Q2 2024 | N/A | -$3.8M | N/A |
| Q3 2023 | N/A | -$1.4M | $-0.08 |
| Q2 2023 | N/A | -$4.4M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Talphera, Inc.. Dividends, Buybacks & Capital Allocation
TLPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Talphera, Inc.. (CIK: 0001427925)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TLPH
What is the AI rating for TLPH?
Talphera, Inc.. (TLPH) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TLPH's key strengths?
Claude: Strong liquidity position with current ratio of 5.30x and quick ratio of 5.01x. Moderate debt-to-equity ratio of 0.31x provides financial flexibility.
What are the risks of investing in TLPH?
Claude: Zero revenue with no clear path to near-term commercialization. Negative operating cash flow of -$3.4M annually creating urgent refinancing need.
What is TLPH's revenue and growth?
Talphera, Inc.. reported revenue of $0.0.
Does TLPH pay dividends?
Talphera, Inc.. does not currently pay dividends.
Where can I find TLPH SEC filings?
Official SEC filings for Talphera, Inc.. (CIK: 0001427925) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TLPH's EPS?
Talphera, Inc.. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TLPH a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Talphera, Inc.. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TLPH stock overvalued or undervalued?
Valuation metrics for TLPH: ROE of -13.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TLPH stock in 2026?
Our dual AI analysis gives Talphera, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TLPH's free cash flow?
Talphera, Inc..'s operating cash flow is $-3.4M, with capital expenditures of $0.0.
How does TLPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.8% (avg: 15%), current ratio 5.30 (avg: 2).